International Congress on Targeted Anticancer Therapies (TAT) 2011 Presentations

Plenary Session 1: Opening Ceremony

• NDDO Honorary Award Lecture 2011: The changing landscape of lung cancer and its treatment - G. Giaccone, USA
• Keynote Lecture: Synthetic lethality in cancer treatment: Current status of PARP inhibitors - A.H. Calvert, UK
• Keynote Lecture: Bridging the gap to utilising whole genome data in drug development - A. Futreal, UK

Plenary Session 2: Targeting Mutated BRAF and KRAS

• Educational lecture: Targeting the Ras-Raf pathway for cancer therapy - J. Luo, USA
• Response and resistance to BRAF inhibitors in melanoma - K. Flaherty, USA
• KRAS mutations in human tumours - M. Broggini, Italy

Plenary Session 3: Miscellaneous Drugs and Targets (1)

• Phase II/pharmacodynamic trial of PD0332991 in patients with Kras mutant colorectal cancer - P.J. O'Dwyer, R. Perini, A. DeMichele, D. Vaughn, W. Sun, B. Giantonio, U. Teitelbaum, S. Randolph, J. Christensen, D. Pryma, C. Divgi (slides not available)
• Pooled analysis of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) following prior systemic therapy - S. Bates, F. Foss, R. Piekarz, S. Horwitz, B. Pro, M. Prince, L. Sokol, M. Greenwood, D. Caballero, P.Borchmann, F. Morschhauser, M. Wilhelm, L. Pinter-Brown, S.Padmanabhan, A. Shustov, J. Wright, M. Kirschbaum, J. Zain, S.L. Allen, E.S. Jaffe, J. Nichols, J. Wolfson, J. Balser, B. Coiffier
• Sym004: A novel synergistic anti-EGFR antibody mixture with superior anti-cancer efficacy - R. Dienstmann, A. Patnaik, A.W. Tolcher, M.W. Pedersen, H.J. Jacobsen, K. Kofoed, J. Petersen, J. Tabernero, M. Kragh
• Definition of dose-limiting toxicity in phase I cancer clinical trials of molecularly targeted agents - C. Le Tourneau, R.A. Razak, H.K. Gan, S. Pop, X. Paoletti

Plenary Session 4: Refining Anti-Angiogenic Therapy: Getting Over the Wall

• Educational lecture: Overview of current strategies and results - L. Ellis, USA
• Strategies to complement VEGF targeted therapies - A. Peterson, USA
• Targeting acquired resistance to angiogenesis inhibitors by targeting HIF-1 - G. Melillo, USA
• Fibroblast growth factors: New drugs to manage a morpheic tumour target - F. de Braud, Italy
• Is the tumour genome helping us to better select patients for anti-angiogenic therapy? - E. Voest, The Netherlands

Plenary Session 5: Targeting DNA Damage Repair Beyond PARP

• PARP as a novel therapeutic target in cancer - C. Annunziata, USA
• Chk inhibitors for the treatment of human malignancies - A. Senderowicz, USA
• Targeting DNA damage repair beyond PARP - further drugs or targets in development - R. Plummer, UK
• Preclinical characterisation of ARRY-575: a potent, selective, and orally bio-available small molecule inhibitor of Chk1 - M.J. Humphries, I. von Carlowitz, Y.L. Le Huerou, N. Randolph, I. Gunawardana, P.J. Mohr, B. Wang, M.A. Lyon, M. Chicarelli, F. Sullivan, J.F. Blake, S.L. Winski, E. Wallace
• Namitecan (ST 1968), a novel camptothecin analogue - C. Sessa, D. Hess, A. Fasolo, R. Calderone, S. Bastian, G. Del Conte, S. De Dosso, N. Hagner, L. Luraghi, S. Pace, N. Coceani, E. Maccioni, L. Gianni (slides not available)

Plenary Session 6: Hsp90 Inhibitors

• Educational lecture: Targeting the molecular chaperone Hsp90 for cancer therapy: What does the biology tell us? - L. Neckers, USA
• Heat shock protein 90 (Hsp90) inhibition as a potential novel approach to the treatment of patients with ALK mutated non-small cell lung cancer (NSCLC) - R. Ross, USA
• Discovery and development of AUY922 - U. Banerji, UK
• Hsp90 inhibitors in clinical development: AT13387 - G. Shapiro, USA
• Hsp90 inhibitors in clinical development: STA-9090 (Ganetespib) - G. Shapiro, USA

Plenary Session 7: Metabolic Targets

• Educational lecture: Metabolic targeting: an update on biguanides - M. Pollak, Canada (slides not available)
• Targeting metabolism: Metformin in cancer prevention and therapy - M. Pierotti, Italy (slides not available)
• Cancer metabolism: Drug discovery to control critical metabolic enzymes - D. Schenkein, USA (slides not available)
• Putting cancer on a diet: Targeting glycolysis and fatty acid metabolism as therapeutic strategies - P. Nisen, USA (slides not available)

Plenary Session 8: Targeting the Androgen Axis and Other Targets in Prostate Cancer

• Educational lecture: New targets and drugs in prostate cancer - C. Sternberg, Italy
• Improving outcome from advanced prostate cancer through rational drug development - J. de Bono, UK
• Tubulin-binding drugs in prostate cancer - C. Massard, France

Plenary Session 9: Methodological and Regulatory Issues in the Development of Targeted Agents

• Report of MDICT Task Force Meeting 2011 - A.H. Calvert, UK
• "What went wrong with aurora kinase inhibitors?" - T. Fojo, USA
• "What went wrong with IGF-1R inhibitors?" - M. Pollak, Canada (slides not available)
• Targeting from a regulatory perspective - B. Jonsson, Sweden (slides not available)

Plenary Session 10: Immunological Targets

• Immunological targets: Basic aspects - I. Melero, Spain (slides not available)
• It's a new world in melanoma - A.M.M. Eggermont, France (slides not available)
• Novel strategies in the design and development of recombinant vaccines for cancer therapy - R.A. Madan, C. Palena, J.L. Gulley, J.W. Hodge, K.Y. Tsang, J.W. Greiner, J. Huang, J. Schlom (slides not available)

Plenary Session 11: Drugs Targeting the PI3K – Akt – mTOR Pathway

• Educational lecture: The PI3K/Akt/mTOR signaling pathway - P. Dennis, USA (slides not available)
• New drugs targeting the PI3K/Akt/mTOR pathway - P. LoRusso, USA
• Targeting the PI3K-Akt-mTOR pathway with GDC-0068, a novel selective ATP competitive Akt inhibitor - J. Tabernero, Spain

Plenary Session 12: Miscellaneous Drugs and Targets (2)

• SMAC mimetics as new anticancer agents - A. Adjei, USA
• PTEN loss induced cellular senescence for "pro-senescence" therapy for cancer - A. Alimonti, Switzerland (slides not available)
• Discovery and development of next generation epigenetic DNMT inhibitors: Development of SGI-110, a novel DNMT inhibitor - J.P. Issa, USA
• HERG1 channels: from antitargets to novel therapeutic targets in oncology - A. Arcangeli, A. Becchetti, O. Crociani, M. D'Amico, L. Gasparoli, M. Masselli, S. Pillozzi, K. Mugridge,W. Tiedke
• Potent inhibition of multiple proteasome subunits by carfilzomib in solid tumour and multiple myeloma patients - S.J. Lee, T.M. Woo, M. Vallone, S. Arastu-Kapur, E.T. Chan, A.F. Wong, M.H. Le, A.L. Hannah, C.J. Kirk.
• Preliminary experience of a phase I clinical trial combining an antiviral approach to chemoradiotherapy for HPV related malignancies - E. Deutsch, C. Haie-Meder, C. Bourgier, M.C. Vozenin, C. Lhomme, J. Bourhis, J.C. Soria (slides not available)

Plenary Session 13: Roles for Genome Sequencing in Drug Development

• Implications of the new sequencing technologies for clinical oncology - P. Meltzer, USA (slides not available)
• An integrated and comprehensive approach of functional and structural genomics at the era of exome and next generation sequencing in early drug development - V. Lazar, France (slides not available)